ClinicalTrials.gg
CompletedNCT00663936Updated Nov 5, 2013

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

A Phase 2 interventional study of T-817MA and Placebo in Alzheimer's Disease, sponsored by FUJIFILM Toyama Chemical Co., Ltd.. Completed at 35 sites in 2 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2013-11-05.

Sponsored by FUJIFILM Toyama Chemical Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
373
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
257th of 1,610
373 · median 73
Started
2008
with 53 others
Phase 2
360 of 1,941
50 open now
Registered
265th of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 257th largest by enrollment of the 1,610 interventional ones that give a count, is one of 54 that started in 2008, is one of 360 in phase 2, and was the 265th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy of T-817MA in AD patients to treat dementia. Efficacy will be cognitive function, as measured by the ADAS-cog cognitive assessment.

The secondary objectives of the study are to evaluate the safety of T-817MA and the activities of daily living (assessed with the ADCS-ADL) of AD patients taking T-817MA, and to evaluate the efficacy of T-817MA in AD patients with an overall global assessment using the ADCS-CGIC.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Alzheimer's Disease
  • Alzheimer's
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ( or surgically sterile)
  2. Patients with Mild to moderate Alzheimer's disease who are receiving Donepezil.
  3. Age 50 to 90 inclusive
  4. Patients must be living in the community
  5. Patients must have an eligible informant or study partner (caregiver)
  6. Patients and eligible informant or study partner (caregiver) must be able to read and understand English.
  7. obtained from both the patient and the caregiver etc (According to the protocol)

Exclusion criteria

Exclusion Criteria:

  1. Patients with cardiac, hepatic or renal impairment
  2. Patient have a dementia not of the Alzheimer's type etc (According to the protocol)
  3. Patients who are taking any drug other than donepezil for Alzheimer's disease, including rivastigmine (Exelon®), galantamine (Razadyne®), memantine (Namenda™) or tacrine (Cognex®) taken within twelve (12) weeks of the Baseline Visit (Visit 2).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
373 participants (actual)

Study arms

  • Experimental
    1

    T-817MA once daily

    Drug: T-817MA

  • Placebo comparator
    2

    Placebo once daily

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluation of the efficacy of T-817MA in AD patients to treat dementia. Efficacy will be cognitive function, as measured by the ADAS-cog cognitive assessment.

    Time frame: 52 weeks

Secondary outcomes

  1. Secondary objectives are to evaluate the safety of T-817MA and the activities of daily living (ADCS-ADL) of AD patients taking T-817MA, and to evaluate the efficacy of T-817MA in AD patients with an overall global assessment using the ADCS-CGIC.

    Time frame: 52 weeks

07

Study locations

35 sites
  • Banner Alzheimer's Institute
    Phoenix, Arizona 85006, United States
  • Northwest NeuroSpecialists
    Tucson, Arizona 85741, United States
  • Collaborative Neuroscience Network, Inc.
    Garden Grove, California 92845, United States
  • Southwest Institute for Clinical Research, Inc.
    Rancho Mirage, California 92270, United States
  • Pacific Research Network, Inc.
    San Diego, California 92103, United States
  • San Francisco Clinical Research Center
    San Francisco, California 94109, United States
  • Radiant Research
    Denver, Colorado 80239, United States
  • Geriatric and Adult Psychiatry, LCC
    Hamden, Connecticut 06518, United States
  • Research Center for Clinical Studies, Inc.
    Norwalk, Connecticut 06851, United States
  • NeuroPsychiatric Center of the Palm Beaches
    Boynton Beach, Florida 33426, United States
  • Galiz Research
    Miami Springs, Florida 33166, United States
  • Anchor Research Center
    Naples, Florida 34102, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Axiom Clinical Research of Florida
    Tampa, Florida 33609, United States
  • Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute
    Tampa, Florida 33613, United States
  • Premiere Research Institute
    West Palm Beach, Florida 33407, United States
  • Columbus Research & Wellness Institute
    Columbus, Georgia 31907, United States
  • Agewell
    Indianapolis, Indiana 46260, United States
  • Cleveland Clinic - Lou Ruvo Center for Brain Health
    Las Vegas, Nevada 89106, United States
  • Comprehensive Clinical Research
    Berlin, New Jersey 08009, United States
  • Memory Enhancement Center of America
    Toms River, New Jersey 08755, United States
  • Brooklyn Medical Institute
    Brooklyn, New York 11214, United States
  • SPRI Clinical Trials
    Brooklyn, New York 11235, United States
  • Alzheimer's Disease Center, U. of Rochester Medical Center
    Rochester, New York 14620, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • The Alzheimer's Memory Center
    Charlotte, North Carolina 28211, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Raleigh Neurology Associates
    Raleigh, North Carolina 27607, United States
  • Clinical Trials of America, Inc.
    Winston Salem, North Carolina 27103, United States
  • The Clinical Trials Center
    Jenkintown, Pennsylvania 19046, United States
  • CRI Worldwide, LLC
    Philadelphia, Pennsylvania 19139, United States
  • Innovative Clinical Trials
    San Antonio, Texas 78229, United States
  • IPC Research
    Waukesha, Wisconsin 53188, United States
  • St. Joseph's Hospital
    St. John, New Brunswick E2L 3L6, Canada
  • Toronto Memory Program
    Toronto, Ontario M3B 2S7, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of May 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2008
First posted
Apr 22, 2008
Start
Apr 2008
Primary completionActual
May 2011
CompletionActual
Jun 2011
Results delay requested
Dec 9, 2012
Last update
Nov 5, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00663936
Lead sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Responsible party
Sponsor
First posted
Apr 22, 2008
Start date
Apr 2008
Primary completion
May 2011
Completion
Jun 2011
Last update
Nov 5, 2013

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: T-817 maleate

Start the discussion